What is Implanon
Approved as Treatment by the FDAEtonogestrel, otherwise called NuvaRing, is approved by the FDA for 1 uses such as Contraceptive implant therapy .
When to interrupt dosageThe suggested measure of Implanon is contingent upon the diagnosed state, including Birth Control, Reproductive Age and Contraceptive implant therapy. The degree of dosage is contingent upon the technique of delivery (e.g. Subcutaneous or Insert, extended release) as listed in the table beneath.
WarningsImplanon has 27 contraindications, so it must not be employed with any of the conditions enumerated in the table below.Implanon Contraindications
Implanon Novel Uses: Which Conditions Have a Clinical Trial Featuring Implanon?A total of 38 active studies are currently assessing the potential of Implanon for Birth Control, Contraceptive Implant Therapy and Hormonal Contraceptive interventions.
Implanon Reviews: What are patients saying about Implanon?
Patient Q&A Section about implanon
How does Implanon work in the body?
"The implant is a contraception method that prevents the ovaries from releasing an egg each month. It also thickens the fluid around the cervix, making it harder for sperm to enter and fertilize an egg." - Anonymous Online Contributor
When was Implanon discontinued?
"Implanon has been discontinued and replaced by Nexplanon as of October 2010 in order to reduce the risk of insertion errors." - Anonymous Online Contributor
Whats the difference between Implanon and Nexplanon?
"The main difference between Implanon and Nexplanon is that Nexplanon has two extra safety features to help ensure proper insertion. Nexplanon has now replaced Implanon and Implanon is no longer being manufactured." - Anonymous Online Contributor
What are Implanon side effects?
"You may experience nausea, stomach cramping/bloating, dizziness, headache, breast tenderness, acne, hair loss, weight gain, or vaginal irritation/discharge. You may also experience pain, bruising, numbness, infection, or scarring at the site where the rod is placed." - Anonymous Online Contributor